Deep Multi-OMICs and Multi-Tissue Characterization in a Pre- and Postprandial State in Human Volunteers: The GEMM Family Study Research Design by Bastarrachea, Raúl A. et al.
genes
G C A T
T A C G
G C A T
Article
Deep Multi-OMICs and Multi-Tissue
Characterization in a Pre- and Postprandial State in
Human Volunteers: The GEMM Family Study
Research Design
Raul A. Bastarrachea 1,*,†, Hugo A. Laviada-Molina 2,†, Edna J. Nava-Gonzalez 3,
Irene Leal-Berumen 4 , Claudia Escudero-Lourdes 5 , Fabiola Escalante-Araiza 6,
Vanessa-Giselle Peschard 6, Rosa A. Veloz-Garza 7, Karin Haack 1,
Angélica Martínez-Hernández 8, Francisco M. Barajas-Olmos 8, Fernanda Molina-Segui 2,
Fatima A. Buenfil-Rello 2, Lucia Gonzalez-Ramirez 2, Reinhard Janssen-Aguilar 2,
Ricardo Lopez-Muñoz 2, Fernanda Perez-Cetina 1, Janeth F. Gaytan-Saucedo 1, Zoila Vaquera 1,
Judith Cornejo-Barrera 9, Juan Carlos Castillo-Pineda 10, Areli Murillo-Ramirez 10,
Sara P. Diaz-Tena 10, Benigno Figueroa-Nuñez 11, Laura González-López 12,
Rocío A. Salinas-Osornio 12, Melesio E. Valencia-Rendón 12, José Ángeles-Chimal 13 ,
Jesús Santa-Olalla Tapia 13 , José M. Remes-Troche 14 , Salvador B. Valdovinos-Chavez 7,
Eira E. Huerta-Avila 1, Xianlin Han 15 , Lorena Orozco 8, Ernesto Rodriguez-Ayala 6,
Susan Weintraub 16, Esther C. Gallegos-Cabrales 7, Shelley A. Cole 1 and Jack W. Kent Jr. 1
1 Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX 78227-0549, USA;
khaack@txbiomed.org (K.H.); maryferpcetina@hotmail.com (F.P.-C.); janethgaytan@gmail.com (J.F.G.-S.);
ZVaquera@txbiomed.org (Z.V.); lneeha920609@gmail.com (E.E.H.-A.); scole@txbiomed.org (S.A.C.);
jkent@txbiomed.org (J.W.K.J.)
2 Escuela de Ciencias de la Salud, Universidad Marista de Mérida, Mérida 97300, Mexico;
hlaviada@marista.edu.mx (H.A.L.-M.); fmolina@marista.edu.mx (F.M.-S.);
ln.fatimabuenfil@hotmail.com (F.A.B.-R.); nut.lucia.gonzalez@hotmail.com (L.G.-R.);
rjanssen91@gmail.com (R.J.-A.); Lopezm.ric@gmail.com (R.L.-M.)
3 Facultad de Salud Pública y Nutrición (FASPyN), UANL, Monterrey 64460, Mexico; edna.navag@uanl.mx
4 Facultad de Medicina y Ciencias Biomédicas, Universidad Autónoma de Chihuahua, Chihuahua 31125,
Mexico; ileal@uach.mx
5 Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí 78240, Mexico;
cescuder@uaslp.mx
6 Centro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud,
Universidad Anáhuac Norte, Lomas Anahuac 52786, Mexico; fescara@gmail.com (F.E.-A.);
vanessa-gisellep@wustl.edu (V.-G.P.); ernesto.rodriguez@anahuac.mx (E.R.-A.)
7 Facultad de Enfermería, Universidad Autónoma de Nuevo León (UANL), Monterrey 64460, Mexico;
rosyvelozgarza@hotmail.com (R.A.V.-G.); svmonterrey@gmail.com (S.B.V.-C.);
esther.gallegosc@gmail.com (E.C.G.-C.)
8 Laboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica,
Ciudad de México C.P. 14610, Mexico; amartinez@inmegen.gob.mx (A.M.-H.);
fbarajas@inmegen.gob.mx (F.M.B.-O.); lorozco@inmegen.gob.mx (L.O.)
9 Departamento de Enseñanza, Postgrado e Investigación, Hospital Infantil de Tamaulipas,
Ciudad Victoria 87150, Mexico; judith.cornejo@tam.gob.mx
10 Departamento de Nutrición Humana, Universidad Latina de América, Morelia, Michoacán 58170, Mexico;
castillomorelia@hotmail.com (J.C.C.-P.); amurillor@unla.edu.mx (A.M.-R.);
ln.sarapatriciadiaz@victoriamedicalcenter.com (S.P.D.-T.)
11 Clínica de Enfermedades Crónicas y Procedimientos Especiales (CECYPE), Morelia 58249, Mexico;
benigno.figueroa@cecype.com
12 Universidad del Valle de Atemajac (UNIVA), Zapopan, Jalisco 45050, Mexico;
laura.gonzalez@univa.mx (L.G.-L.); rocio.salinas@univa.mx (R.A.S.-O.); tantarrea@gmail.com (M.E.V.-R.)
13 Facultad de Medicina, Universidad Autónoma Estado de Morelos, Cuernavaca 62209, Mexico;
chimal@uaem.mx (J.Á.-C.); jsa@uaem.mx (J.S.-O.T.)
Genes 2018, 9, 532; doi:10.3390/genes9110532 www.mdpi.com/journal/genes
Genes 2018, 9, 532 2 of 16
14 Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz 91700, Mexico;
jose.remes.troche@gmail.com
15 Department of Medicine, Sam and Ann Barshop Institute for Longevity and Aging Studies,
University of Texas Health San Antonio, San Antonio, TX 78229, USA; HanX@uthscsa.edu
16 Department of Biochemistry, University of Texas Health Science Center, San Antonio, TX 78229, USA;
weintraub@uthscsa.edu
* Correspondence: raul@txbiomed.org
† These authors contributed equally to this work.
Received: 22 September 2018; Accepted: 29 October 2018; Published: 2 November 2018


Abstract: Cardiovascular disease (CVD) and type 2 diabetes (T2D) are increasing worldwide. This is
mainly due to an unhealthy nutrition, implying that variation in CVD risk may be due to variation in
the capacity to manage a nutritional load. We examined the genomic basis of postprandial metabolism.
Our main purpose was to introduce the GEMM Family Study (Genetics of Metabolic Diseases in
Mexico) as a multi-center study carrying out an ongoing recruitment of healthy urban adults. Each
participant received a mixed meal challenge and provided a 5-hours’ time course series of blood,
buffy coat specimens for DNA isolation, and adipose tissue (ADT)/skeletal muscle (SKM) biopsies
at fasting and 3 h after the meal. A comprehensive profiling, including metabolomic signatures in
blood and transcriptomic and proteomic profiling in SKM and ADT, was performed to describe
tendencies for variation in postprandial response. Our data generation methods showed preliminary
trends indicating that by characterizing the dynamic properties of biomarkers with metabolic activity
and analyzing multi-OMICS data it could be possible, with this methodology and research design,
to identify early trends for molecular biology systems and genes involved in the fasted and fed states.
Keywords: multi-OMICS; GEMM family study; postprandial metabolism; mixed meal challenge
1. Introduction
Mexicans share with Mexican Americans an elevated risk of cardiovascular diseases (CVD) and
type 2 diabetes (T2D) [1]. In the US, Mexican Americans have the highest age-adjusted prevalence
of the metabolic syndrome (31.9%) [2]. In a population-based survey in the Republic of Mexico,
the prevalence of the metabolic syndrome was 26.6% [3]. This shared, elevated prevalence of CVD risk
factors suggests shared genetic factors. As the source population, Mexico reflects the allelic diversity
resulting from the conquest and subsequent confluence of European and Native American origins,
and therefore reflects the full extent of the spectrum of risk [4]. Because Hispanics, including Mexican
Americans, are among the fastest growing population groups in the US, knowledge gained from the
source population will directly inform public health initiatives in the US [5].
The GEMM (Genética de las Enfermedades Metabólicas en México/Genetics of Metabolic Diseases
in Mexico Family Study) is a bi-national, multi-center collaborative study of cardiovascular risk
phenotypes of metabolic origin (CVRMO) related to T2D and the risk of CVD [6]. The overall goal
of this project is to identify the genetic and molecular processes involved in the development of
these major public health threats in an effort to better diagnose and treat those who are afflicted
or at risk [7]. Scientific oversight and coordination of GEMM is provided by a steering committee
comprising investigators at Texas Biomedical Research Institute (Texas Biomed), San Antonio, TX,
USA and the Mexican National Institute of Genomic Medicine (INMEGEN). Ten participating centers
in Mexico have been carefully selected based on their affiliation with a medical university and/or
teaching hospital. Each center has obtained funding in Mexico, including very substantial institutional
commitments of resources and personnel, to set up a state-of-the-art diagnostic facility dedicated to
GEMM and recruit participants [8] (Figure 1).
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The vast majority of studies and clinical diagnosis of metabolic diseases have been focused on the
fasted state [9]. However, it has been suggested that atherosclerotic changes start to develop in the
pre-diabetic state [10]. Accumulating evidence suggests that postprandial hyperglycemia and elevated
levels of postprandial lipoproteins predict higher CVD risk [11]. Postprandial hypertriglyceridemia is a
recognized independent predictor of cardiovascular pathology [12]. Our interest is in the normal range
of variation of CVRMO phenotypes in apparently healthy individuals, including subtle differences in
metabolic processes that can point to novel biomarkers of incipient disease. Deep phenotyping [13],
as it is proposed in this study, is likely to improve accuracy in classification of disease outcomes,
relative to earlier epidemiological and clinical studies, by providing comprehensive, individualized
profiles of risk.
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Figure 1. Map of Mexico showing location of GEMM (Genetics of Metabolic Diseases in Mexico) Centers.
The GEMM family study design characterizes detailed dynamic and function-based metabolic
phenotypes in fasting and fed states (including the phenome, transcriptome, proteome and
metabolome) [14]. Data are acquired from the circulation, adipose tissue and skeletal muscle,
tissues that are key for understanding insulin action and carbohydrate and lipid homeostasis.
All measurements in blood are taken over a time course of 5 h to allow fine-scale profiling of individual
postprandial response.
The aims of this paper are (a) to introduce the GEMM family study research design aimed
at characterizing the individual response to a mixed meal challenge, in order to define the range
of efficiency of nutrient utilization in nominally healthy individuals in a population at risk of
cardiometabolic disease; and (b) to present preliminary application of the research design to 16 female
participants to show the full clinical and molecular phenotypic characterization expected to occur in
our final database.
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2. Materials and Methods
2.1. Recruitment of Study Participants
Families are ascertained and recruited following established guidelines and strategies for
processes of recruitment in prospective family-based studies [15]. The ideal proband for recruitment is
healthy, aged 25–45 years, and both parents are also healthy, alive and willing to participate. Once
a proband is enrolled, an invitation to participate in the study will be extended to all relatives of
first, second or third degree (e.g., parents, children, grandparent/grandchild, avuncular, cousins, etc.)
who are at least 18 years of age, their spouses, and the proband’s spouse and the spouse’s relatives
aged 18 or above. Our goal is to recruit 400 healthy volunteers in ~10 extended families (40 subjects
from each of the participating centers), ascertained without regard to disease status [16]. Figure 2
represents the pedigree of a typical family recruited in this study from Monterrey, Nuevo Leon,
Mexico. All participants provide written, informed consent, and all procedures are approved by
the Ethical Committees (Institutional Review Boards) of the respective centers. Export of GEMM
samples for multi-OMICs analysis to the USA. has been permitted by the Mexican Federal government
in accordance with Mexican genetic sovereignty law [17] (COFEPRIS Permit No. COF187278
(DEAPE 133300CT190038/2013) issued on 19 March 2013) [18]. This family-based study is currently
approved by the Institutional Review Board at the University of Texas Health Sciences Center at
San Antonio (IRB Number HSC20170448H) and is conducted according to the principles expressed in
the declaration of Helsinki.
1 
 
 
Figure 2. Three-generation family tree from Monterrey, Mexico as an example of the typical extended
pedigrees recruited in the GEMM Study. Proband: MTY1001 (P002). Proband’s wife: MTY1002
(P004). Founders: MTY 10050&51 (deceased). Proband’s parents: MTY1002&03 (deceased). Brothers
and sisters: MTY 1011, 10, 08, 13 (P0014), 09, 12, 14. Daughters: MTY1006 (P021) and 07 (P018).
Son: MTY 1005 (P022). P00: Participants that have already volunteered for the postprandial/biopsy
procedures. Female—circles; Male—squares.
2.2. Study Timeline and Standardization of Postprandial Procedures
The capability for each center is up to four individuals a month when the Center is in operation.
A typical day in the center is as follows:
2.2.1. First Visit
Study participant arrives after a 12 h overnight fast. On arrival, fasting anthropometric
measurements were recorded: weight, height, waist circumference, body mass index (BMI), and
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body composition by bioimpedance. Blood pressure and heart rate is also measured. First (fasting)
measurement of energy expenditure with MedGem (Microlife, Clearwater Florida, USA), an indirect
calorimetry clinically-validated and Food and Drug Administration (FDA)-approved medical device
for measurement of resting metabolic rate (RMR) [19]. An IV line and catheter are placed in the median
basilic vein of the forearm and a fasting blood sample (#0, time 0 min) is taken. Immediately after,
participant ingests his/her mixed meal as 30% of Total Daily Energy Expenditure (TDEE). Postprandial
blood samples #1 (15 min), #2 (30 min), #3 (45 min), #4 (60 min), #5 (90 min) follow. Second evaluation
of RMR with MedGem (postprandial) is performed. Postprandial sample #6 (120 min) and #7 (180 min)
follow. Immediately after, postprandial muscle (100 mg) and subcutaneous adipose tissue (160 mg)
biopsies are obtained from the right thigh by a surgeon, serving as the postprandial tissue biopsy
3 h after meal ingestion. Postprandial blood samples #8 (240 min) and #9 (300 min) are taken. Third
evaluation of RMR with MedGem (postprandial) is performed. Immediately after, the IV catheter is
removed, subject is given lunch and dismissed.
2.2.2. Second Visit (14 Days after the First Visit)
On arrival after a 12 h fast, total body bone and tissue composition densitometry (DXA-GE Lunar
Prodigy GE Healthcare, Madison, WI, USA) is performed. Blood pressure and heart rate are measured.
Immediately after, the second muscle (100 mg) and adipose tissue (160 mg) biopsies in fasting are
obtained from the left thigh. Subject is given breakfast and dismissed.
2.3. Anthropometric Measurement, Body Composition and Indirect Calorimetry
Waist circumference is measured with a professional Gulick tape measure (North Coast Medical, Inc.,
Morgan Hill, CA, USA) in centimeters. Height is determined by a fixed HM200P Portstad Portable
stadiometer (Quick Medical, Issaquah, WA, USA). Methods used for measurement of weight
and bioimpedance (Tanita BC—418 Body Composition Analyzer, (Hanover, MD, USA) [20], body
composition by dual energy X-ray absorptiometry (DXA-GE Lunar Prodigy) [21]), and RMR by indirect
calorimetry (MedGem) have been described previously [19].
2.4. Mixed Meal Challenge
Having fasted overnight, each participant consumes a defined mixed meal (Ensure Plus®; Abbott
Nutrition, Lake Forest, IL, USA) containing 57% of total calories from carbohydrates, 28% from fat,
and 15% from protein. The amount of the mixed meal provided is calculated by a staff dietician to
provide 30% of the participant’s daily energy requirement based on total body weight (Harris–Benedict
equation) and fat free mass (kg) (Katch–McArdle formula) [22].
2.5. Hormone, Cytokine and Clinical Chemistry Measurements for Postprandial Metabolic Assessments
Biochemical phenotypes are analyzed on a Luminex 100IS platform (SBH Sciences, Natick,
MA, USA) and an Immulite 1000 (Diamond Diagnostics Inc., Holliston, MA, USA) which run
enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA) analyses. We measure a
wide range of clinical biochemistries, hormones, cytokines and endophenotypes (Tables 1–3). These
analyte categories included: Gastrointestinal biomarkers (satiety signals: GLP-1, PYY, Ghrelin; β cell
and insulin-glucose axis: insulin, glucose, HOMA-IR, Matsuda Index; Adipose tissue function:
leptin, adiponectin; Inflammation endophenotypes: C-RP high sensitive, PAI-1, TNF-α, MCP-1;
Lipid-lipoprotein metabolism: NEFA, tryglycerides, HDL-C.)
2.6. Fasting and Postprandial Plasma Metabolomic Profiling of Amino Acids and Acylcarnitines
The derivatized amino acids are analyzed by high-performance liquid chromatography-electrospray
ionisation–mass spectrometry (HPLC-ESI-MS) on a Q Exactive mass spectrometer (Thermo Fisher
Scientific, Austin, TX, USA) used together with a Dionex Ultimate 3000 HPLC (Thermo Fisher
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Scientific) [23]. Extracted ion chromatograms were generated for the protonated molecule for each
derivatized amino acid using a mass window of ±5 ppm. Peak areas are determined by processing
through TraceFinder (Thermo Fisher Scientific) and compared to calibration curves generated by
analysis of authentic standards.
2.7. Acylcarnitines
Lipids are extracted using ice-cold chloroform/methanol (2:1) (Millipore Sigma, St. Louis, MO,
USA), with addition of water as needed to generate a two-phase system. A bead homogenizer was
used for tissue homogenization. Palmitoyl-[1,2,3,4-13C4] L-carnitine internal standard (Adventbio
Chyrstal Chem, Elk Grove Village, IL, USA) is added at the time of extraction. After centrifugation
the chloroform layer was removed, dried in vacuo and reconstituted in injection solution.
HPLC-ESI-tandem-MS analyses was conducted on a Q Exactive mass spectrometer (Thermo Fisher)
used in conjunction with a Thermo Fisher/Dionex Ultimate 3000 HPLC (Thermo Fisher Scientific) [24].
TraceFinder (Thermo Fisher Scientific) was used for processing of the quantitative data.
2.8. Transcriptomics: RNA Gene Expression Profiling
Total RNA is isolated from skeletal muscle and subcutaneous adipose tissue [25]. Messenger RNA
(mRNA) (from total RNA) is converted into a complementary DNA (cDNA) library using the Illumina
TruSeq Stranded mRNA sample preparation kit (Illumina Inc., San Diego, CA, USA). PolyA mRNAs is
preferentially selected from 0.1–4 ug of high-quality total RNA using magnetic beads covered with
poly-T oligos (TriLink Biotechnologies, San Diego, CA, USA). The mRNAs undergo a first and second
strand cDNA synthesis resulting in a double-strand complementary DNA (dscDNA) with blunt ends.
After ligation of an adapter, the products are purified and enriched by polymerase chain reaction
(PCR) to create the final cDNA libraries [26]. The preliminary data reported here were generated
using Illumina Sentrix Human Whole Genome WG-6 microarrays. We have begun re-analysis of these
samples by RNA sequencing and will employ this technology for all future analyses.
2.9. Statistical Analysis
For this initial presentation of GEMM data, we obtained summary statistics in R (www.r-project.org)
and tests for differences by BMI and feeding status (pre- vs. postprandial). The latter tests were
performed using SOLAR [27] to account for the random effect of kinship and included age as covariate.
2.10. Interpretation and Power
The goal of this analysis is to identify those features that are differentially altered by the meal
challenge according to prior assessment of cardiometabolic risk, as these are the gene products (and by
extension, the genes) most relevant to individual variation in cardiovascular risk of metabolic origin
(CVRMO). Given our preliminary data, we expect to find relatively robust effects of both meal challenge
and CVRMO stratum. The two-way ANOVA for differential response to meal by stratum will provide
80% power to detect a medium effect of about 6% of variance, based on analysis of ~100 significantly
differing features (pcrit = 0.0005).
2.11. Correction for Admixture
The Mexican population has a complex genetic history, blending Native American, European,
and Afro-Caribbean ancestry. Our decision to recruit extended families, and to account for
explicit relatedness as described in the preceding section, provides one level of adjustment for this
non-independence. In addition, we will address potential cryptic relatedness due to population history
by performing principal components analysis (PCA) on single nucleotide polymorphism (SNP) data
from the Multi-Ethnic AMR/AFR-8 arrays [28] and using principal components as covariates in our
analyses to correct for population stratification [29].
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3. Results
In this section we report baseline and postprandial data from 16 healthy female adult individuals
characterized with all fasting and postprandial anthropometric, biochemical, and OMICS data as
will be obtained for the full database we are assembling. These data should be appraised as an
example of the types of data that the GEMM protocol will collect as well as an assessment of the
range of variation in these data. While some of our results are suggestive of possible pathways and
mechanisms of metabolic flexibility, we acknowledge that this preliminary sample is too small to be
conclusive. Here we present OMICS data from skeletal muscle and plasma from 16 female subjects.
Preliminary data for amino acids and acylcarnitines (AcC) only shows branched-chain amino acid
(BCCA) profiling and long-chain AcC species (Table 3). Of note, our ongoing protocol has already
recruited and collected anthropometric, body composition, buffy coats, fasting and postprandial
plasma, subcutaneous adipose and muscle tissue biopsies from 126 healthy volunteers.
These 16 females were divided in two groups by the lower mean (n = 8, 24 ± 1.6, max = 26.6,
min = 20.7) and higher mean (n = 8, 32.1 ± 5.7, max = 41.6, min = 26.8) levels of BMI. Their mean
age was 34.1 ± 14.4 y.o. in the lower mean BMI (l.BMI), and 41.2 ± 11.0 y.o. in the higher mean BMI
group (h.BMI). Tables 1–3 describe their differential fasting and fed physiologic and endophenotypic
parameters fully characterized with clinical biochemistries, hormones, cytokines and metabolite
measures (amino acids and AcC).
Consistent with other reports, our data showed that leptin levels were higher in the group of h.BMI
in the fasting and fed state. However, the fasting circulating levels of leptin in both groups did not
change after the mixed meal administration (fasting levels of 8.6± 5.6 and postprandial levels (300 min)
of 9.4 ± 5.9 ng/mL in the l.BMI group vs. fasting levels of 18.6 ± 9.3 and postprandial levels (300 min)
of 16.4 ± 8.2 ng/mL in the h.BMI group, Table 1) [30]. Our methodology proposal/development data
also showed fasting adiponectin levels of 19.9± 13.2 µg/mL in the l.BMI group and 22.6 ± 19.6 µg/mL
in the h.BMI group [31].
Among the gut-derived satiety hormones implicated in control of food intake, the orexigenic
ghrelin showed higher fasting levels in the subjects with l.BMI (333.5 ± 59.1 pg/mL) compared to
subjects with h.BMI (233.1 ± 137.2 pg/mL). The ghrelin pattern followed the documented preprandial
rise [32], falling to lower levels within the following 30– 120 min after the mixed meal, rising
back again during the next 180 min and 300 min. The pre- and postprandial curves of the satiety
peptides GLP-1 and PYY increased after the meal ingestion, returning to fasting levels after 300 min.
The fasting pro-inflammatory cytokines measured trended higher in the h.BMI compared to the l.BMI
subjects (TNFα: 1.8 ± 0.7 vs. 1.4 ± 1.1 pg/mL; hs-CRP: 0.42 ± 0.30 vs. 0.09 ± 0.07 mg/L; PAI-1:
66,901.4 ± 56,005.3 vs. 43,527.9 ± 38,563.4 pg/mL; IL-6: 2.1 ± 1.6 vs. 1.9 ± 1.3 pg/mL) (Table 1).
Preprandial and postprandial glucose, insulin, non-esterified free fatty acids (NEFA), tryglcerides
and high-density lipoprotein cholesterol (HDL-C) concentrations after the ingestion of the mixed meal
challenge are shown in Table 2. Fasting insulin was higher in the in the h.BMI compared to the l.BMI
subjects. Postprandial NEFA at 180 min, fasting and postprandial HDL-C at 180 min and 300 min were
higher in the in the h.BMI compared to the l.BMI subjects. The homeostasis model assessment (HOMA)
index [33] was higher in subjects with h.BMI than in l.BMI participants. Whole-body physiological
insulin sensitivity was estimated by calculating the Matsuda index [34]. h.BMI subjects reported an
index of 4.89 ± 3.59 compared to l.BMI counterparts reporting 6.66 ± 4.05 (Table 2).
The postprandial quantitative data on amino acids obtained from these 16 healthy females
revealed an interesting pattern showing that in the women with the lower BMI the vast majority
of essential amino acids was differentially elevated in the fed state (alanine, arginine, asparagine,
glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, proline, serine, threonine,
tryptophan, valine) when compared to their counterparts with a higher BMI (aspartic acid, cysteine,
glutamic acid, phenylalanine) (Table 3). We also measured AcC in the serum by MS/MS. Among all
AcC measured, we focus on the long-chain AcC species (C14:0, C14:1, C14:2, C14:3, C16:0, C16:1, C16:2,
C18:0, C18:1, C18:2, C18:3) due to their association with insulin resistance [35]. We observed that only
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2 AcC species (30′postprandial AcC C14:3, and 300′ postprandial AcC C16:0), showed a noticeable
differential measurement in the h.BMI compared to the l.BMI subjects (Table 3).
For transcriptomics preliminary data we are including a small pilot study of muscle gene
expression using transcriptomic array data. Figure 3 and Table 4 show preliminary data for 9 GEMM
participants from the same cohort of 16 healthy females for fasting vs. 3 h postprandial skeletal
muscle tissue gene expression. These 9 females were divided in three groups (n = 3 each) with a
BMI < 25, 25–30, and >30–32 transcripts were differentially expressed after the meal at a nominal
p < 0.05. The two most strongly differentially expressed transcripts in muscle show a similar pattern:
lower response in obese vs. healthy weight, and greater variation in the overweight (Figure 3).
Table 1. Fasting and postprandial phenotypes related to body composition, adipocyte biology, incretins,
hunger and satiety, and immune system activity.
Lower BMI Values (n = 8) Higher BMI Values (n = 8)
24 ± 1.6 32.1 ± 5.7
Anthropometric and Clinical Measurements
Age 34.1 ± 14.4 41.2 ± 11.0
Height (cm) 152.4 ± 6.0 151.9 ± 3.6
Weight (kg) 56.1 ± 7.9 74.1 ± 14.0
Waist Circumference (cm) 76.6 ± 4.5 95.3 ± 11.4
Fat Total (%) 39.1 ± 4.5 46.5 ± 4.7
Fat Mass Total (kg) 20.9 ± 5.0 33.4 ± 8.3
Muscle Mass Total (kg) 31.9 ± 3.2 37.8 ± 6.3
Avg. Systolic Pressure (mmHg) 107.7 ± 7.8 109.6 ± 12.5
Avg. Diastolic Pressure (mmHg) 67.5 ± 3.9 70.8 ± 7.7
Adipose Tissue Hormones
Fasting Adiponectin (µg/mL) 19.9 ± 13.2 22.6 ± 19.6
Fasting Leptin (ng/mL) 8.6 ± 5.6 18.6 ± 9.3
Postprandial Leptin (30 min) 7.9 ± 5.1 18.0 ± 9.9
Postprandial Leptin (60 min) 8.1 ± 5.0 17.8 ± 9.4
Postprandial Leptin (120 min) 8.5 ± 5.9 16.6 ± 9.1
Postprandial Leptin (180 min) 9.3 ± 6.1 16.7 ± 8.1
Postprandial Leptin (300 min) 9.4 ± 5.9 16.4 ± 8.2
Gastrointestinal Satiety Signals
Fasting GLP1 121.9 ± 56.8 136.3 ± 45.5
Postprandial GLP1 30 min 147.9 ± 48.8 189.5 ± 63.1
Postprandial GLP1 60 min 123.0 ±47.6 151.1 ± 58.2
Postprandial GLP1 120 min 130.4 ± 53.1 143.8 ± 64.2
Postprandial GLP1 180 min 120.4 ± 49.1 138.8 ± 51.6
Postprandial GLP1 300 min 123.1 ± 61.8 145.0 ± 64.6
Fasting PYY 54.2 ± 46.5 35.1± 51.2
Postprandial PYY 30 min 70.6 ± 24.8 121.2 ± 74.8
Postprandial PYY 60 min 83.8 ± 65.3 94.3 ± 52.8
Postprandial PYY 120 min 75.7 ± 52.1 79.7 ± 51.8
Postprandial PYY 180 min 82.1 ± 56.3 86.8 ± 63.7
Postprandial PYY 300 min 75.8 ± 44.8 76.1 ± 66.5
Fasting Ghrelin 333.5 ± 59.1 233.1 ± 137.2
Postprandial Ghrelin 30 min 274.1 ± 50.2 192.2 ± 127.2
Postprandial Ghrelin 60 min 220.9 ± 41.2 166.1 ± 116.6
Postprandial Ghrelin 120 min 206.7 ± 44.6 155.6 ± 106.1
Postprandial Ghrelin 180 min 211 ± 66.4 152.9 ± 108.9
Postprandial Ghrelin 300 min 249.6 ± 76.4 157.2 ± 124.8
Adipocytokines and Inflammatory Biomarkers
TNFα 1.4 ± 1.1 1.8 ± 0.7
hs-CPR 0.09 ± 0.07 0.42 ± 0.30
PAI-1 43,527.9 ± 38,563.4 66,901.4 ± 56,005.3
IL-6 1.9 ± 1.3 2.1 ± 1.6
BMI: body mass index; avg: average.
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Table 2. Fasting and postprandial phenotypes related to the insulin-glucose axis, lipid-lipoprotein
metabolism and insulin-mediated glucose disposal.
Lower BMI Values (n = 8) Higher BMI Values (n = 8)
24 ± 1.6 32.1 ± 5.7
Insulin-Glucose Axis
Fasting Glucose (mg/dL) 84.3 ± 4.9 87.9 ± 7.0
Postprandial Glucose (30 min) (mg/dL) 116.5 ± 9.57 107.8 ± 11.4
Postprandial Glucose (60 min) (mg/dL) 119.25 ± 27.09 115.62 ± 13.83
Postprandial Glucose (120 min) (mg/dL) 114.5 ± 17.07 115.62 ± 19.15
Postprandial Glucose (180 min) (mg/dL) 101.25 ± 16.42 99.37 ± 9.83
Postprandial Glucose (300 min) (mg/dL) 93.62 ± 14.16 92.25 ± 4.65
Fasting Insulin (uIU/mL) 11.04 ± 10.01 16.64 ± 10.41
Postprandial Insulin (30 min) (uIU/mL) 63.81 ± 29.78 78.29 ± 42.78
Postprandial Insulin (60 min) (uIU/mL) 72.53 ± 42.82 84.03 ± 60.51
Postprandial Insulin (120 min) (uIU/mL) 51.09 ± 22.65 54.27 ± 36.19
Postprandial Insulin (180 min) (uIU/mL) 31.46 ± 12.45 41.85 ± 25.79
Postprandial Insulin (300 min) (uIU/mL) 16.94 ± 14.40 27.65 ± 18.52
HOMA-IR 2.31 ± 2.17 3.68 ± 2.34
Matsuda Index 6.66 ± 4.05 4.89 ± 3.59
Lipid-Lipoprotein Metabolism
Fasting NEFA (mEq/L) 0.7 ± 0.1 0.7 ± 0.1
Postprandial NEFA (30 min) (mEq/L) 0.5 ± 0.2 0.7 ± 0.1
Postprandial NEFA (60 min) (mEq/L) 0.2 ± 0.1 0.4 ± 0.2
Postprandial NEFA (120 min) (mEq/L) 0.1 ± 0.1 0.2 ± 0.1
Postprandial NEFA (180 min) (mEq/L) 0.1 ± 0.1 0.3 ± 0.2
Postprandial NEFA (300 min) (mEq/L) 0.5 ± 0.3 0.5 ± 0.2
Fasting Triglyceride (mg/dL) 89.9 ± 27.2 161.7 ± 47.0
Postprandial Triglyceride (30 min) (mg/dL) 84.3 ± 27.0 157.6 ± 33.6
Postprandial Triglyceride (60 min) (mg/dL) 90.6 ± 27.3 165.1 ± 41.1
Postprandial Triglyceride (120 min) (mg/dL) 92.4 ± 31.2 186.8 ± 55.4
Postprandial Triglyceride (180 min) (mg/dL) 103.0 ± 39.1 209.1 ± 75.3
Postprandial Triglyceride (300 min) (mg/dL) 108.1 ± 44.0 204.8 ± 61.2
Fasting HDL-Col 58.5 ± 13.6 48.9 ± 6.4
Postprandial HDL-Col (180 min) 55.0 ± 14.3 46.8 ± 6.3
Postprandial HDL-Col (300 min) 55.6 ± 15.1 46.3 ± 6.6
NEFA: non-esterified free fatty acids; HDL-C: High-density lipoprotein cholesterol.
Table 3. Fasting and postprandial phenotypes related to metabolomics, amino acid signatures
and acylcarnitine.
Lower BMI Values (n = 8) Higher BMI Values (n = 8)
24 ± 1.6 32.1 ± 5.7
Metabolomics Profiling
Targeted Aminoacid Signature
Branched-chain (BCCA) amino acids
Isoleucine 0 min 42.5 ± 7.2 41.8 ± 5.0
Isoleucine 30 min 73.3 ± 14.5 51.6 ± 11.28
Isoleucine 180 min 63.1 ± 10.8 50.1 ± 8.5
Isoleucine 300 min 55.5 ± 6.6 50.6 ± 9.7
Leucine 0 min 77.8 ± 10.2 80.8 ± 14.7
Leucine 30 min 125.3 ± 19.8 95.6 ± 21.1
Leucine 180 min 99.8 ± 13.6 85.8 ± 15.6
Leucine 300 min 88.1 ± 9.7 81.02 ± 12.9
Valine 0 min 141.9 ± 24.7 153.1 ± 38.9
Valine 30 min 183.9 ± 34.9 167.1 ± 47.8
Valine 180 min 171.4 ± 22.2 159.4 ± 36.6
Valine 300 min 162.4 ± 11.2 159.5 ± 32.3
Phenylalanine 0 min 43.05 ± 3.13 53. 7 ± 8.1
Phenylalanine 30 min 57.3 ± 5.7 59.6 ± 8.8
Phenylalanine 180 min 53.9 ± 4.9 56.9 ± 7.8
Phenylalanine 300 min 48.2 ± 5.01 55.3 ± 7.5
Aspartic acid 0 min 3.9 ± 2.1 6.1 ± 1.6
Aspartic acid 30 min 2.7 ± 1.7 3.7 ± 2.2
Aspartic acid 180 min 2.3 ± 1.5 2.5 ± 2
Aspartic acid 300 min 3.05 ± 1.2 4.6 ± 2.5
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Table 3. Cont.
Lower BMI Values (n = 8) Higher BMI Values (n = 8)
Targeted Acylcarnitine Signature
Acylcarnitine (14:0) 0 min 0.2 ± 0.07 0.2 ± 0.06
Acylcarnitine (14:0) 30 min 0.2 ± 0.6 0.2 ± 0.06
Acylcarnitine (14:0) 180 min 0.07 ± 0.02 0.1 ± 0.07
Acylcarnitine (14:0) 300 min 0.09 ± 0.06 0.1 ± 0.05
Acylcarnitine (14:1) 0 min 0.7 ± 0.5 0.1 ± 0.2
Acylcarnitine (14:1) 30 min 0.7 ± 0.5 0.1 ± 0.1
Acylcarnitine (14:1) 180 min 0.2 ± 0.2 0.04 ± 0.04
Acylcarnitine (14:1) 300 min 0.4 ± 0.4 0.03 ± 0.02
Acylcarnitine (14:2) 0 min 0.6 ± 0.3 0.2 ± 0.05
Acylcarnitine (14:2) 30 min 0.4 ± 0.2 0.2 ± 0.06
Acylcarnitine (14:2) 180 min 0.2 ± 0.08 0.2 ± 0.09
Acylcarnitine (14:2) 300 min 0.3 ± 0.3 0.2 ± 0.02
Acylcarnitine (14:3) 0 min 0.06 ± 0.03 0.03 ± 0.005
Acylcarnitine (14:3) 30 min 0.05 ± 0.02 0.02 ± 0.003
Acylcarnitine (14:3) 180 min 0.03 ± 0.01 0.02 ± 0.01
Acylcarnitine (14:3) 300 min 0.05 ± 0.04 0.02 ± 0.005
Acylcarnitine (16:0) 0 min 1.6 ± 0.2 1.5 ± 0.3
Acylcarnitine (16:0) 30 min 1.4 ± 0.2 1.5 ± 0.3
Acylcarnitine (16:0) 180 min 0.8 ± 0.2 1.2 ± 0.4
Acylcarnitine (16:0) 300 min 0.8 ± 0.1 1.1 ± 0.3
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Table 4. Gene expression nominally up- or down-regulated at 3 h postprandium relative to fasting
levels in nine female subjects (t-test, p < 0.05).
Probe Accession Gene Symbol p-Value Direction of Change
ILMN_1684982 NM_002612.3 PDK4 0.00000106 up
ILMN_1697448 NM_006472.2 TXNIP 0.0000279 up
ILMN_1791728 NM_052901.2 SLC25A25 0.000232157 down
ILMN_1663092 NM_006079.3 CITED2 0.000454775 up
ILMN_1691846 NM_015714.2 G0S2 0.000530702 down
ILMN_1661519 NM_014702.3 KIAA0408 0.000559434 up
ILMN_1907042 AK123264 C1orf132 0.000903385 up
ILMN_1794017 NM_013376.3 SERTAD1 0.00102915 down
ILMN_1728699 NM_194285.2 SPTY2D1 0.001347097 down
ILMN_1874689 AB074162 MIR181A2HG 0.001811776 down
ILMN_1797031 NM_024610.4 HSPBAP1 0.002114313 up
ILMN_1860963 BM715829 transcribed locus 0.00277532 down
ILMN_1710284 NM_005524.2 HES1 0.002894267 down
ILMN_1839665 BQ186372 transcribed locus 0.002993048 up
ILMN_1908530 AW003529 miR-205 0.003042844 down
ILMN_1776483 GDS5231 no annotation 0.003499501 up
ILMN_1689212 NM_001010892.1 RSHL3 0.004134486 down
ILMN_2186061 NM_004566.2 PFKFB3 0.004236655 up
ILMN_1870041 AJ227862 partial mRNA 0.004322057 up
ILMN_1771618 NM_173671.1 FLJ37396 0.004436233 down
ILMN_3266471 GDS5431 no annotation 0.005104923 down
ILMN_2077680 NM_152353.1 CLDND2 0.005149724 up
ILMN_1764873 NM_001419.2 ELAVL1 0.005480716 down
ILMN_1756006 NM_015104.1 ATG2A 0.005654292 up
ILMN_3262439 GDS5167 no annotation 0.006327375 down
ILMN_1732750 NM_016565.2 CHCHD8 0.006543098 down
ILMN_1704022 NM_207316.1 TMEM207 0.006752015 down
ILMN_2044927 NM_006913.2 RNF5 0.007227478 down
ILMN_1741392 NM_000387.3 SLC25A20 0.007466004 up
ILMN_1786242 GDS3855 no annotation 0.008237115 up
ILMN_1836309 GDS3531 no annotation 0.008873484 down
ILMN_3245678 NC_000001.11 RNU1-1 0.009334803 up
4. Discussion
Our discussion highlights and summarizes the two main prongs of the GEMM Family Study:
(I) the potential academic and scientific scope of GEMM’s research design; and (II) the implications
of the data obtained from the first 16 female healthy volunteers considered as an example of the
methodology proposal/development of GEMM’s research design as we anticipate to obtain in our
final database.
I (a). The GEMM Family study’s overarching scientific premise is that inter-individual variation
in risk of CVD, T2D and other cardiometabolic diseases is due in part to variation in flexibility and
efficiency in disposing of a meal bolus, and this variation may be more readily observed postprandially
than at fasting. Our approach includes both a novel, individualized meal challenge (a healthy
combination of carbohydrates, protein, and fat calibrated to each subject’s energy requirement) and
comprehensive measurement of OMICS data—individualized profiling of gene action in response to
the meal. Such a focus on the genetic response following the consumption of a nutritionally defined
meal at the level of the specific tissues involved (i.e., fat and muscle), will produce new insights into
the genetic architecture of individual variation in metabolism of carbohydrates, fats and proteins,
and how this variation in response relates to risk for a variety of chronic diseases including obesity,
diabetes and heart disease.
I (b). GEMM focuses on Mexican nationals. However, genetic epidemiology has shown that
Mexicans share with Mexican Americans an elevated prevalence of CVD risk factors [36], suggesting
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shared genetic factors. As mentioned earlier, Mexico, as the source population, is likely to retain more
of the allelic diversity obtained through the admixture from the Conquest, when European and Native
Americans began interbreeding. Studying the genetics of CVD risk factors in Mexican nationals could
have a strong impact on future public health policies for US-born Mexican Americans or individuals
of Mexican origin living in the USA [37].
I (c). The GEMM protocol includes an innovative mixed meal challenge [38] containing a
well-defined macronutrient composition based on recommended daily values (Ensure Plus®) [39],
dosed at 30% of each subject’s daily resting energy expenditure allowing a much greater opportunity
to screen for early postprandial detection of an adverse metabolic response. It has been documented
that risk factors for adverse cardiovascular events can be detected in the pre-diabetic insulin-resistant
subject based upon the metabolic response to a meal challenge even in the absence of altered fasting
parameters. The superiority of a mixed meal versus the oral glucose tolerance test, related to cardiac
dysfunction, has been proposed to relate to the postprandial hypertriglyceridemia which only occurred
using the mixed meal [40].
I (d). GEMM interrogates the genomic and physiologic basis of postprandial metabolism by
measuring dynamic phenotypes. Our study is designed to unravel metabolic responses both at the
molecular and physiological level, characterizing a response to a nutritional challenge across a time
course and in more than one tissue, which appears to be the better tool to reveal metabolic disturbances,
compared to single-point measurements at the static fasting state. Our innovative postprandial study
design measures biochemical trajectories that differ from static measurements in the same way motion
pictures differ from snapshots: the dimension of time is included. Our approaches for measuring
molecular, biochemical, metabolic and clinical dynamics are therefore fundamentally different from
the conventional approach of measuring static concentrations [41].
I (e). GEMM uses combined multi-OMIC, multi-tissue data to address hypotheses about variable
response to feeding. By repeatedly measuring both biochemical and intermediate molecular markers
in the circulation across a time course, we are able to observe individual differences in macronutrient
uptake and disposal in unprecedented detail. Similarly, by obtaining high-dimensional transcriptomic,
proteomic, and metabolomic measures from skeletal muscle and adipose tissue biopsies from the
same individuals at fasting and 3 h after the meal, we will acquire integrated profiles of gene action in
response to feeding in a key tissue for macronutrient homeostasis.
II (a). Regarding our proposal/development data, we reiterate that the reason to present a small
number of subjects (n = 16) is solely to illustrate the development purposes of the methodology.
The changes described in the preliminary results confirm prior studies, including the higher levels
of leptin and ghrelin, the increase in the inflammatory/cardiovascular risk marker, CRP, and the
presence of insulin resistance in the subjects with higher BMI levels (Table 1). The postprandial leptin,
insulin levels and gastrointestinal satiety signals involved in neurohormonal regulation of energetic
homeostasis (GLP-1, PYY), the fasting inflammatory biomarkers (TNFα, hs-CRP, PAI-1, IL-6), and the
biochemistry markers of lipid-lipoprotein metabolism (NEFA, triglycerides, C-HDL), clearly showed a
trend to be elevated in our group with higher BMI values, except for postprandial ghrelin lower levels
(Tables 1 and 2). A low C-HDL, and high levels of NEFA, triglycerides, IL-6, TNF-α and CRP have
been previously implicated in the development of insulin resistance [42].
II (b). Concordantly, our subjects with a h.BMI were less insulin sensitive than the group with
l.BMI. by two independent criteria HOMA-IR [33] and the Matsuda Index [34]. The latter is considered
a dynamic measure for whole body insulin sensitivity. 2.5 or less of Matsuda Index have been used
to find subjects with insulin resistance [43]. The Matsuda Index in our preliminary data shows a
trend of a lower Index in the group with h.BMI. The HOMA-IR derives from measurements of fasting
plasma glucose and insulin concentrations primarily reflecting hepatic insulin resistance [44]. The best
cutoff of HOMA-IR for identifying Americans of Mexican descent with insulin resistance are reference
values <2.60 as the normal range, HOMA-IR 2.60–3.80 as ‘borderline high’ without labeling these
Genes 2018, 9, 532 13 of 16
individuals as having insulin resistance, and HOMA-IR >3.80 as ‘high’ having clear correlates of
insulin resistance [45]. Our group with h.BMI reported a HOMA-IR of 3.68 (Table 2).
II (c). Table 3 shows our preliminary results on postprandial targeted amino acid signatures.
Recent large-scale metabolite profiling studies have highlighted alterations in essential amino acid
metabolism that mark the obese, insulin-resistant phenotype [46]. However, most studies that have
examined blood amino acid patterns in obesity and T2DM have been conducted in the overnight- to
extended-fasting state. There is no evidence that obesity or insulin resistance alters renal processing of
blood amino acids, indicating that the observed fasting blood amino acid patterns are not likely a direct
reflection of dietary-derived amino acids or differences in urinary excretion of these metabolites.
Therefore, it is fair to suggest that all assumptions such as the ones from the results of fasting
branched-chain amino acids (BCAA) patterns and insulin resistance should be taken with caution,
unless the postprandial state is included as a means of differential comparison with fasting [47].
II (d). For our small pilot study of muscle gene expression (Figure 3) we found 32 differentially
expressed transcripts in muscle (p < 0.05). 15 of those transcripts were upregulated and 7 were
downregulated after the mixed meal. Two genes were significantly expressed (p < 10−5): PDK4
and TXNIP. PDK4 is abundant in pancreatic islets and in skeletal muscles that have high glucose
utilization and fatty acid oxidation rates [48]. It has been recently reported that the gene expression of
thioredoxin-interacting protein (TXNIP) in the skeletal muscle decreased with caloric restriction and
the degree of TXNIP downregulation was associated with the rate of glucose disposal during clamp
measurements [49].
In summary, GEMM combines integrated, multi-OMIC profiles with novel postprandial
intermediate molecular biomarkers to identify biochemical pathways and potential regulatory
networks, thereby identifying some of the earliest markers of metabolic dysregulation and CVRMO
that may indicate future T2D and CVD. These preliminary results are firm steps which would help
define the range of variation in metabolic flexibility, and therefore early risk of cardiometabolic disease,
in nominally healthy individuals. The GEMM study should pave the way for the identification of
novel biomarkers of cardiometabolic risk which will have a positive impact on public health initiatives
for dealing with these serious conditions, both in Mexico and, possibly, in the rapidly-growing
Mexican-American community in the US.
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